Before conducting more work to make the model more relevant to miRNA detection it would benefit
from improving the detection limit, as currently the detection system needs to be at least 200x lower.
This could be done by amplifying the DNA/RNA before detection, improving the transduction
133
134
References
1. Jensen, E.C. Quantitative Analysis of Histological Staining and Fluorescence Using Imagej.
Anat Rec 296, 378-381 (2013).
2. McKhann, G., Drachman, D., Folstein, M. et al. Clinical Diagnosis of Alzheimer's Disease: Report of the Nincds-Adrda Work Group under the Auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944 (1984). 3. Dowrick, A. & Southern, A. Dementia 2014 Opportunity for Change Report. Alzheimer
Society (2014).
4. Yiannopoulou, K.G. & Papageorgiou, S.G. Current and Future Treatments for Alzheimer’s Disease. Therapeutic Advances in Neurological Disorders 6, 19-33 (2013).
5. Hodge, S. & Hailey, E. Second English National Memory Clinics Audit Report. Royal College of
Psychiatrists (2015).
6. Bamford, C., Eccles, M., Steen, N. et al. Can Primary Care Record Review Facilitate Earlier Diagnosis of Dementia? Fam Pract 24, 108-116 (2007).
7. Dodd, E., Cheston, R. & Ivanecka, A. The Assessment of Dementia in Primary Care. Journal of
Psychiatric and Mental Health Nursing 22, 731-737 (2015).
8. Davidson, J. Prime Minister's Challenge on Dementia. Department of Health (2012).
9. Ohm, T.G., Müller, H., Braak, H. et al. Close-Meshed Prevalence Rates of Different Stages as a Tool to Uncover the Rate of Alzheimer's Disease-Related Neurofibrillary Changes.
Neuroscience 64, 209-217 (1995).
10. Mattsson, N., Carrillo, M.C., Dean, R.A. et al. Revolutionizing Alzheimer's Disease and Clinical Trials through Biomarkers. Alzheimers Dement (Amst) 1, 412-419 (2015).
11. Lewis, F., Karlsberg Schaffer, S., Sussex, J. et al. The Trajectory of Dementia in the Uk – Making a Difference. Alzheimer Research UK (2014).
12. Rinne, J.O., Brooks, D.J., Rossor, M.N. et al. 11c-Pib Pet Assessment of Change in Fibrillar Amyloid-Beta Load in Patients with Alzheimer's Disease Treated with Bapineuzumab: A Phase 2, Double-Blind, Placebo-Controlled, Ascending-Dose Study. Lancet Neurol 9, 363-372 (2010).
13. Salloway, S., Sperling, R., Fox, N.C. et al. Two Phase 3 Trials of Bapineuzumab in Mild-to- Moderate Alzheimer's Disease. N Engl J Med 370, 322-333 (2014).
14. Doody, R.S., Thomas, R.G., Farlow, M. et al. Phase 3 Trials of Solanezumab for Mild-to- Moderate Alzheimer's Disease. N Engl J Med 370, 311-321 (2014).
15. Brooker, D., La Fontaine, J., Evans, S. et al. Public Health Guidance to Facilitate Timely Diagnosis of Dementia: Alzheimer's Cooperative Valuation in Europe Recommendations. Int J
Geriatr Psychiatry 29, 682-693 (2014).
16. Dubois, B., Padovani, A., Scheltens, P. et al. Timely Diagnosis for Alzheimer’s Disease: A Literature Review on Benefits and Challenges. Journal of Alzheimer's Disease 49, 617-631 (2015).
17. Carpenter, B.D., Xiong, C., Porensky, E.K. et al. Reaction to a Dementia Diagnosis in Individuals with Alzheimer's Disease and Mild Cognitive Impairment. J Am Geriatr Soc 56, 405-412 (2008).
18. Iliffe, S., Manthorpe, J. & Eden, A. Sooner or Later? Issues in the Early Diagnosis of Dementia in General Practice: A Qualitative Study. Fam Pract 20, 376-381 (2003).
19. Bruandet, A., Richard, F., Bombois, S. et al. Alzheimer Disease with Cerebrovascular Disease and Vascular Dementia: Clinical Features and Course Compared with Alzheimer Disease. J
Neurol Neurosurg Psychiatry 80, 133-139 (2009).
20. Banerjee, S. & Wittenberg, R. Clinical and Cost Effectiveness of Services for Early Diagnosis and Intervention in Dementia. Int J Geriatr Psychiatry 24, 748-754 (2009).
135 21. Getsios, D., Blume, S., Ishak, K.J. et al. An Economic Evaluation of Early Assessment for
Alzheimer's Disease in the United Kingdom. Alzheimers Dement 8, 22-30 (2012).
22. Gaugler, J.E., Ascher-Svanum, H., Roth, D.L. et al. Characteristics of Patients Misdiagnosed with Alzheimer's Disease and Their Medication Use: An Analysis of the Nacc-Uds Database.
BMC Geriatr 13, 137 (2013).
23. Gauthier, S., Leuzy, A., Racine, E. et al. Diagnosis and Management of Alzheimer's Disease: Past, Present and Future Ethical Issues. Prog Neurobiol 110, 102-113 (2013).
24. Mattsson, N., Brax, D. & Zetterberg, H. To Know or Not to Know: Ethical Issues Related to Early Diagnosis of Alzheimer's Disease. Int J Alzheimers Dis 2010 (2010).
25. Nakamura, A., Kaneko, N., Villemagne, V.L. et al. High Performance Plasma Amyloid-Beta Biomarkers for Alzheimer's Disease. Nature 554, 249-254 (2018).
26. Henderson, A.S., Strotzka, H., Lipowski, Z. et al. The Icd-10 Classification of Mental and Behavioural Disorders. World Health Organisation (1993).
27. Braak, H. & Braak, E. Neuropathological Stageing of Alzheimer-Related Changes. Acta
Neuropathol 82, 239-259 (1991).
28. Masters, C.L., Simms, G., Weinman, N.A. et al. Amyloid Plaque Core Protein in Alzheimer- Disease and Down Syndrome. Proc Natl Acad Sci U S A 82, 4245-4249 (1985).
29. Ballard, C., Mobley, W., Hardy, J. et al. Dementia in Down's Syndrome. The Lancet Neurology
15, 622-636 (2016).
30. Kang, J., Lemaire, H.G., Unterbeck, A. et al. The Precursor of Alzheimer's Disease Amyloid A4 Protein Resembles a Cell-Surface Receptor. Nature 325, 733-736 (1987).
31. van der Kant, R. & Goldstein, L.S.B. Cellular Functions of the Amyloid Precursor Protein from Development to Dementia. Developmental Cell 33, 240-240 (2015).
32. Grosgen, S., Grimm, M.O., Friess, P. et al. Role of Amyloid Beta in Lipid Homeostasis. Biochim
Biophys Acta 1801, 966-974 (2010).
33. Soscia, S.J., Kirby, J.E., Washicosky, K.J. et al. The Alzheimer's Disease-Associated Amyloid Beta-Protein Is an Antimicrobial Peptide. PLoS One 5, e9505 (2010).
34. Weingarten, M.D., Lockwood, A.H., Hwo, S.Y. et al. Protein Factor Essential for Microtubule Assembly. Proc Natl Acad Sci U S A 72, 1858-1862 (1975).
35. Ksiezakreding, H., Liu, W.K. & Yen, S.H. Phosphate Analysis and Dephosphorylation of Modified Tau Associated with Paired Helical Filaments. Brain Res 597, 209-219 (1992). 36. Kopke, E., Tung, Y.C., Shaikh, S. et al. Microtubule-Associated Protein-Tau - Abnormal
Phosphorylation of a Non-Paired Helical Filament Pool in Alzheimer-Disease. Journal of
Biological Chemistry 268, 24374-24384 (1993).
37. Lindwall, G. & Cole, R.D. Phosphorylation Affects the Ability of Tau-Protein to Promote Microtubule Assembly. Journal of Biological Chemistry 259, 5301-5305 (1984).
38. Sengupta, A., Kabat, J., Novak, M. et al. Phosphorylation of Tau at Both Thr 231 and Ser 262 Is Required for Maximal Inhibition of Its Binding to Microtubules. Archives of Biochemistry
and Biophysics 357, 299-309 (1998).
39. Alonso, A.D., Mederlyova, A., Novak, M. et al. Promotion of Hyperphosphorylation by Frontotemporal Dementia Tau Mutations. Journal of Biological Chemistry 279, 34873-34881 (2004).
40. Abraha, A., Ghoshal, N., Gamblin, T.C. et al. C-Terminal Inhibition of Tau Assembly in Vitro and in Alzheimer's Disease. Journal of Cell Science 113, 3737-3745 (2000).
41. Thal, D.R., Schultz, C., Dehghani, F. et al. Amyloid Beta-Protein (Abeta)-Containing Astrocytes Are Located Preferentially near N-Terminal-Truncated Abeta Deposits in the Human
Entorhinal Cortex. Acta Neuropathol 100, 608-617 (2000).
42. Grothe, M.J., Barthel, H., Sepulcre, J. et al. In Vivo Staging of Regional Amyloid Deposition.
Neurology 89, 2031-2038 (2017).
43. Tulving, E. & Markowitsch, H.J. Episodic and Declarative Memory: Role of the Hippocampus.
136 44. Villemagne, V.L., Burnham, S., Bourgeat, P. et al. Amyloid Β Deposition, Neurodegeneration,
and Cognitive Decline in Sporadic Alzheimer's Disease: A Prospective Cohort Study. The
Lancet Neurology 12, 357-367 (2013).
45. Driscoll, I. & Troncoso, J. Asymptomatic Alzheimer’s Disease: A Prodrome or a State of Resilience? Curr Alzheimer Res 8, 330-335 (2011).
46. Price, J.L., McKeel, D.W., Jr., Buckles, V.D. et al. Neuropathology of Nondemented Aging: Presumptive Evidence for Preclinical Alzheimer Disease. Neurobiol Aging 30, 1026-1036 (2009).
47. Mrak, R.E., Griffin, S.T. & Graham, D.I. Aging-Associated Changes in Human Brain. J
Neuropathol Exp Neurol 56, 1269-1275 (1997).
48. O’Brien, R.J., Resnick, S.M., Zonderman, A.B. et al. Neuropathologic Studies of the Baltimore Longitudinal Study of Aging (Blsa). J Alzheimers Dis 18, 665-675 (2009).
49. Hyman, B.T. The Neuropathological Diagnosis of Alzheimer's Disease: Clinical-Pathological Studies. Neurobiol Aging 18, S27-32 (1997).
50. Morris, J.C., Storandt, M., McKeel, D.W., Jr. et al. Cerebral Amyloid Deposition and Diffuse Plaques in "Normal" Aging: Evidence for Presymptomatic and Very Mild Alzheimer's Disease.
Neurology 46, 707-719 (1996).
51. SantaCruz, K.S., Sonnen, J.A., Pezhouh, M.K. et al. Alzheimer Disease Pathology in Subjects without Dementia in 2 Studies of Aging: The Nun Study and the Adult Changes in Thought Study. J Neuropathol Exp Neurol 70, 832-840 (2011).
52. Snowdon, D.A. Aging and Alzheimer's Disease: Lessons from the Nun Study. Gerontologist
37, 150-156 (1997).
53. Sonnen, J.A., Larson, E.B., Crane, P.K. et al. Pathological Correlates of Dementia in a Longitudinal, Population-Based Sample of Aging. Ann Neurol 62, 406-413 (2007).
54. Mufson, E.J., Malek-Ahmadi, M., Perez, S.E. et al. Braak Staging, Plaque Pathology and Apoe Status in Elderly Persons without Cognitive Impairment. Neurobiology of Aging 37, 147-153 (2016).
55. Stern, Y. Cognitive Reserve. Neuropsychologia 47, 2015-2028 (2009).
56. Riley, K.P., Jicha, G.A., Davis, D. et al. Prediction of Preclinical Alzheimer's Disease: Longitudinal Rates of Change in Cognition. J Alzheimers Dis 25, 707-717 (2011).
57. Rodrigue, K.M., Kennedy, K.M. & Park, D.C. Beta-Amyloid Deposition and the Aging Brain.
Neuropsychology review 19, 436-450 (2009).
58. Oh, H., Madison, C., Baker, S. et al. Dynamic Relationships between Age, Amyloid-Β Deposition, and Glucose Metabolism Link to the Regional Vulnerability to Alzheimer’s Disease. Brain 139, 2275-2289 (2016).
59. Gu, Y., Razlighi, Q.R., Zahodne, L.B. et al. Brain Amyloid Deposition and Longitudinal Cognitive Decline in Nondemented Older Subjects: Results from a Multi-Ethnic Population.
PLoS One 10, e0123743 (2015).
60. Schwarz, C.G., Kantarci, K., Vemuri, P. et al. Longitudinal Tau Pet in Ageing and Alzheimer’s Disease. Brain 141, 1517-1528 (2018).
61. Tsartsalis, S., Xekardaki, A., Hof, P.R. et al. Early Alzheimer-Type Lesions in Cognitively Normal Subjects. Neurobiol Aging 62, 34-44 (2018).
62. Hu, J., Akama, K.T., Krafft, G.A. et al. Amyloid-Beta Peptide Activates Cultured Astrocytes: Morphological Alterations, Cytokine Induction and Nitric Oxide Release. Brain Res 785, 195- 206 (1998).
63. Salminen, A., Ojala, J., Kauppinen, A. et al. Inflammation in Alzheimer's Disease: Amyloid- Beta Oligomers Trigger Innate Immunity Defence Via Pattern Recognition Receptors. Prog
Neurobiol 87, 181-194 (2009).
64. Davalos, D., Grutzendler, J., Yang, G. et al. Atp Mediates Rapid Microglial Response to Local Brain Injury in Vivo. Nat Neurosci 8, 752-758 (2005).
137 65. Minter, M.R., Taylor, J.M. & Crack, P.J. The Contribution of Neuroinflammation to Amyloid
Toxicity in Alzheimer's Disease. J Neurochem 136, 457-474 (2016).
66. Smith, J.A., Das, A., Ray, S.K. et al. Role of Pro-Inflammatory Cytokines Released from Microglia in Neurodegenerative Diseases. Brain Res Bull 87, 10-20 (2012).
67. Bushong, E.A., Martone, M.E., Jones, Y.Z. et al. Protoplasmic Astrocytes in Ca1 Stratum Radiatum Occupy Separate Anatomical Domains. J Neurosci 22, 183-192 (2002).
68. Nagy, J.I. & Rash, J.E. Connexins and Gap Junctions of Astrocytes and Oligodendrocytes in the Cns. Brain Res Brain Res Rev 32, 29-44 (2000).
69. Giaume, C. & Venance, L. Intercellular Calcium Signaling and Gap Junctional Communication in Astrocytes. Glia 24, 50-64 (1998).
70. Oberheim, N.A., Takano, T., Han, X. et al. Uniquely Hominid Features of Adult Human Astrocytes. J Neurosci 29, 3276-3287 (2009).
71. Abbott, N.J., Ronnback, L. & Hansson, E. Astrocyte-Endothelial Interactions at the Blood- Brain Barrier. Nat Rev Neurosci 7, 41-53 (2006).
72. Cabezas, R., Avila, M., Gonzalez, J. et al. Astrocytic Modulation of Blood Brain Barrier: Perspectives on Parkinson's Disease. Front Cell Neurosci 8, 211 (2014).
73. Jayakumar, A.R., Panickar, K.S., Curtis, K.M. et al. Na-K-Cl Cotransporter-1 in the Mechanism of Cell Swelling in Cultured Astrocytes after Fluid Percussion Injury. J Neurochem 117, 437- 448 (2011).
74. Kirischuk, S., Parpura, V. & Verkhratsky, A. Sodium Dynamics: Another Key to Astroglial Excitability? Trends Neurosci 35, 497-506 (2012).
75. Dani, J.W., Chernjavsky, A. & Smith, S.J. Neuronal Activity Triggers Calcium Waves in Hippocampal Astrocyte Networks. Neuron 8, 429-440 (1992).
76. Garwood, C.J., Ratcliffe, L.E., Simpson, J.E. et al. Review: Astrocytes in Alzheimer's Disease and Other Age-Associated Dementias: A Supporting Player with a Central Role. Neuropathol
Appl Neurobiol 43, 281-298 (2017).
77. Di Castro, M.A., Chuquet, J., Liaudet, N. et al. Local Ca2+ Detection and Modulation of Synaptic Release by Astrocytes. Nat Neurosci 14, 1276-1284 (2011).
78. Allen, N.J. Astrocyte Regulation of Synaptic Behavior. Annu Rev Cell Dev Biol 30, 439-463 (2014).
79. Halassa, M.M., Fellin, T. & Haydon, P.G. The Tripartite Synapse: Roles for Gliotransmission in Health and Disease. Trends Mol Med 13, 54-63 (2007).
80. Nedergaard, M., Ransom, B. & Goldman, S.A. New Roles for Astrocytes: Redefining the Functional Architecture of the Brain. Trends Neurosci 26, 523-530 (2003).
81. Perea, G., Navarrete, M. & Araque, A. Tripartite Synapses: Astrocytes Process and Control Synaptic Information. Trends Neurosci 32, 421-431 (2009).
82. Shigetomi, E., Bowser, D.N., Sofroniew, M.V. et al. Two Forms of Astrocyte Calcium Excitability Have Distinct Effects on Nmda Receptor-Mediated Slow Inward Currents in Pyramidal Neurons. J Neurosci 28, 6659-6663 (2008).
83. Gittis, A.H. & Brasier, D.J. Neuroscience. Astrocytes Tell Neurons When to Listen Up. Science
349, 690-691 (2015).
84. Sattler, R. & Rothstein, J.D. Regulation and Dysregulation of Glutamate Transporters. Handb
Exp Pharmacol, 277-303 (2006).
85. Seifert, G., Schilling, K. & Steinhauser, C. Astrocyte Dysfunction in Neurological Disorders: A Molecular Perspective. Nat Rev Neurosci 7, 194-206 (2006).
86. Chung, W.S., Clarke, L.E., Wang, G.X. et al. Astrocytes Mediate Synapse Elimination through Megf10 and Mertk Pathways. Nature 504, 394-400 (2013).
87. Lian, H., Litvinchuk, A., Chiang, A.C. et al. Astrocyte-Microglia Cross Talk through Complement Activation Modulates Amyloid Pathology in Mouse Models of Alzheimer's Disease. J Neurosci 36, 577-589 (2016).
138 88. Schummers, J., Yu, H. & Sur, M. Tuned Responses of Astrocytes and Their Influence on
Hemodynamic Signals in the Visual Cortex. Science 320, 1638-1643 (2008).
89. Wolf, F. & Kirchhoff, F. Neuroscience. Imaging Astrocyte Activity. Science 320, 1597-1599 (2008).
90. Zonta, M., Angulo, M.C., Gobbo, S. et al. Neuron-to-Astrocyte Signaling Is Central to the Dynamic Control of Brain Microcirculation. Nat Neurosci 6, 43-50 (2003).
91. MacVicar, B.A. & Newman, E.A. Astrocyte Regulation of Blood Flow in the Brain. Cold Spring
Harb Perspect Biol 7 (2015).
92. Gordon, G.R., Choi, H.B., Rungta, R.L. et al. Brain Metabolism Dictates the Polarity of Astrocyte Control over Arterioles. Nature 456, 745-749 (2008).
93. Takano, T., Tian, G.F., Peng, W. et al. Astrocyte-Mediated Control of Cerebral Blood Flow.
Nat Neurosci 9, 260-267 (2006).
94. Brown, A.M. & Ransom, B.R. Astrocyte Glycogen and Brain Energy Metabolism. Glia 55, 1263-1271 (2007).
95. Occhipinti, R., Somersalo, E. & Calvetti, D. Astrocytes as the Glucose Shunt for Glutamatergic Neurons at High Activity: An in Silico Study. J Neurophysiol 101, 2528-2538 (2009).
96. Proia, P., Schiera, G., Mineo, M. et al. Astrocytes Shed Extracellular Vesicles That Contain Fibroblast Growth Factor-2 and Vascular Endothelial Growth Factor. Int J Mol Med 21, 63-67 (2008).
97. Goss, J.R., O'Malley, M.E., Zou, L. et al. Astrocytes Are the Major Source of Nerve Growth Factor Upregulation Following Traumatic Brain Injury in the Rat. Exp Neurol 149, 301-309 (1998).
98. Walicke, P., Cowan, W.M., Ueno, N. et al. Fibroblast Growth Factor Promotes Survival of Dissociated Hippocampal Neurons and Enhances Neurite Extension. Proc Natl Acad Sci U S A
83, 3012-3016 (1986).
99. Sofroniew, M.V., Howe, C.L. & Mobley, W.C. Nerve Growth Factor Signaling, Neuroprotection, and Neural Repair. Annu Rev Neurosci 24, 1217-1281 (2001).
100. Cragnolini, A.B., Volosin, M., Huang, Y. et al. Nerve Growth Factor Induces Cell Cycle Arrest of Astrocytes. Dev Neurobiol 72, 766-776 (2012).
101. Cragnolini, A.B., Huang, Y., Gokina, P. et al. Nerve Growth Factor Attenuates Proliferation of Astrocytes Via the P75 Neurotrophin Receptor. Glia 57, 1386-1392 (2009).
102. Daneman, R. & Prat, A. The Blood-Brain Barrier. Cold Spring Harb Perspect Biol 7, a020412 (2015).
103. Ballabh, P., Braun, A. & Nedergaard, M. The Blood-Brain Barrier: An Overview: Structure, Regulation, and Clinical Implications. Neurobiol Dis 16, 1-13 (2004).
104. Sofroniew, M.V. Reactive Astrocytes in Neural Repair and Protection. Neuroscientist 11, 400- 407 (2005).
105. Heneka, M.T., Sastre, M., Dumitrescu-Ozimek, L. et al. Focal Glial Activation Coincides with Increased Bace1 Activation and Precedes Amyloid Plaque Deposition in App[V717i]
Transgenic Mice. J Neuroinflammation 2, 22 (2005).
106. Beauquis, J., Pavia, P., Pomilio, C. et al. Environmental Enrichment Prevents Astroglial Pathological Changes in the Hippocampus of App Transgenic Mice, Model of Alzheimer's Disease. Exp Neurol 239, 28-37 (2013).
107. Carter, S.F., Scholl, M., Almkvist, O. et al. Evidence for Astrocytosis in Prodromal Alzheimer Disease Provided by 11c-Deuterium-L-Deprenyl: A Multitracer Pet Paradigm Combining 11c- Pittsburgh Compound B and 18f-Fdg. J Nucl Med 53, 37-46 (2012).
108. Beach, T.G. & McGeer, E.G. Lamina-Specific Arrangement of Astrocytic Gliosis and Senile Plaques in Alzheimer's Disease Visual Cortex. Brain Res 463, 357-361 (1988).
109. Griffin, W.S., Stanley, L.C., Ling, C. et al. Brain Interleukin 1 and S-100 Immunoreactivity Are Elevated in Down Syndrome and Alzheimer Disease. Proc Natl Acad Sci U S A 86, 7611-7615 (1989).
139 110. Korolainen, M.A., Auriola, S., Nyman, T.A. et al. Proteomic Analysis of Glial Fibrillary Acidic
Protein in Alzheimer's Disease and Aging Brain. Neurobiol Dis 20, 858-870 (2005). 111. Kamphuis, W., Mamber, C., Moeton, M. et al. Gfap Isoforms in Adult Mouse Brain with a
Focus on Neurogenic Astrocytes and Reactive Astrogliosis in Mouse Models of Alzheimer Disease. PLoS One 7, e42823 (2012).
112. Allaman, I., Gavillet, M., Belanger, M. et al. Amyloid-Beta Aggregates Cause Alterations of Astrocytic Metabolic Phenotype: Impact on Neuronal Viability. J Neurosci 30, 3326-3338 (2010).
113. Heneka, M.T., Carson, M.J., El Khoury, J. et al. Neuroinflammation in Alzheimer's Disease.
Lancet Neurol 14, 388-405 (2015).
114. Medeiros, R. & LaFerla, F.M. Astrocytes: Conductors of the Alzheimer Disease Neuroinflammatory Symphony. Exp Neurol 239, 133-138 (2013).
115. Simpson, J.E., Ince, P.G., Lace, G. et al. Astrocyte Phenotype in Relation to Alzheimer-Type Pathology in the Ageing Brain. Neurobiol Aging 31, 578-590 (2010).
116. Ogata, K. & Kosaka, T. Structural and Quantitative Analysis of Astrocytes in the Mouse Hippocampus. Neuroscience 113, 221-233 (2002).
117. Kimelberg, H.K. The Problem of Astrocyte Identity. Neurochem Int 45, 191-202 (2004). 118. Olabarria, M., Noristani, H.N., Verkhratsky, A. et al. Concomitant Astroglial Atrophy and
Astrogliosis in a Triple Transgenic Animal Model of Alzheimer's Disease. Glia 58, 831-838 (2010).
119. Yeh, C.Y., Vadhwana, B., Verkhratsky, A. et al. Early Astrocytic Atrophy in the Entorhinal Cortex of a Triple Transgenic Animal Model of Alzheimer's Disease. ASN Neuro 3, 271-279 (2011).
120. Kulijewicz-Nawrot, M., Verkhratsky, A., Chvatal, A. et al. Astrocytic Cytoskeletal Atrophy in the Medial Prefrontal Cortex of a Triple Transgenic Mouse Model of Alzheimer's Disease. J
Anat 221, 252-262 (2012).
121. Simpson, J.E., Ince, P.G., Shaw, P.J. et al. Microarray Analysis of the Astrocyte Transcriptome in the Aging Brain: Relationship to Alzheimer's Pathology and Apoe Genotype. Neurobiol
Aging 32, 1795-1807 (2011).
122. Pike, C.J., Cummings, B.J., Monzavi, R. et al. Beta-Amyloid-Induced Changes in Cultured Astrocytes Parallel Reactive Astrocytosis Associated with Senile Plaques in Alzheimer's Disease. Neuroscience 63, 517-531 (1994).
123. Abramov, A.Y., Canevari, L. & Duchen, M.R. Changes in Intracellular Calcium and Glutathione in Astrocytes as the Primary Mechanism of Amyloid Neurotoxicity. J Neurosci 23, 5088-5095 (2003).
124. Rossner, S., Lange-Dohna, C., Zeitschel, U. et al. Alzheimer's Disease Beta-Secretase Bace1 Is Not a Neuron-Specific Enzyme. J Neurochem 92, 226-234 (2005).
125. Hartlage-Rubsamen, M., Zeitschel, U., Apelt, J. et al. Astrocytic Expression of the Alzheimer's Disease Beta-Secretase (Bace1) Is Stimulus-Dependent. Glia 41, 169-179 (2003).
126. Blasko, I., Veerhuis, R., Stampfer-Kountchev, M. et al. Costimulatory Effects of Interferon- Gamma and Interleukin-1beta or Tumor Necrosis Factor Alpha on the Synthesis of Abeta1-40 and Abeta1-42 by Human Astrocytes. Neurobiol Dis 7, 682-689 (2000).
127. Iliff, J.J., Wang, M., Liao, Y. et al. A Paravascular Pathway Facilitates Csf Flow through the Brain Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid Beta. Sci Transl
Med 4, 147ra111 (2012).
128. Zeppenfeld, D.M., Simon, M., Haswell, J.D. et al. Association of Perivascular Localization of